Evaluation of the use of mass chemoprophylaxis during a school outbreak of enzyme type 5 serogroup B meningococcal disease

Pediatric Infectious Disease Journal

Volumn 15, Issue 11, 1996, Pages 992-998

  Jackson, Lisa A ^a,e   Alexander, E Russell ^a,b   Debolt, Charla A ^b   Swenson, Paul D ^b   Boase, Janice ^b   Mcdowell, Michael G ^c   Reeves, Michael W ^d   Wenger, Jay D ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b PUBLIC HEALTH SEATTLE AND KING COUNTY   (United States)

^c WASHINGTON STATE DEPARTMENT OF HEALTH   (United States)

^d NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

antibiotic resistance; chemoprophylaxis; disease outbreak; meningococcal disease; Neisseria meningitidis

Indexed keywords

MENINGOCOCCUS VACCINE; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ARTICLE; HUMAN; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; SCHOOL; TREATMENT OUTCOME;

ADOLESCENT; ANTIBIOTICS, ANTITUBERCULAR; CARRIER STATE; CHILD; DISEASE OUTBREAKS; DRUG RESISTANCE, MICROBIAL; FEMALE; HUMANS; MALE; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS; OROPHARYNX; RIFAMPIN; RISK FACTORS; SCHOOLS; SEROTYPING;

EID: 0029807114     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199611000-00012     Document Type: Article

References (34)

1. Caugant DA, Frohølm LO, Bøvre K, et al. Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc Natl Acad Sci USA 1986;83:4927-31.
2. Sacchi CT, Pessoa LL, Ramos SR, et al. Ongoing group B Neisseria meningitidis in Sao Paulo, Brazil, due to increased prevalence of a single clone of the ET-5 complex. J Clin Microbiol 1992;30:1734-8.
3. Cruz C, Pavez G, Aguilar E, et al. Serotype-specific outbreak of group B meningococcal disease in Iquique, Chile. Epidemiol Infect 1990;105:119-26.
4. Tappero J, Gassibe P, Castillo L, Reeves M, Perkins B. Epidemic of clonal serogroup B meningococcal disease in Chile [Abstract J-13]. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 4 to 7, 1994.
5. Centers for Disease Control and Prevention. Serogroup B meningococcal disease: Oregon, 1994. MMWR 1995;44: 121-4.
6. Fischer M, Diermayer M, Hedberg K, et al. Emergence of epidemic group B meningococcal disease in the United States [Abstract K-159]. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 4 to 7, 1994.
7. Reeves MW, Perkins BA, Diermayer M, Wenger JD. Epidemic-associated Neisseria meningitidis detected by multilocus enzyme electrophoresis. Emerg Infect Dis 1995;1:53-4.
8. Sierra GVG, Campa HC, Varcacel NM, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991;14:195-207.
9. Bjune G, Høiby EA, Grønnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991;338:1093-6.
10. Boslego JB, Garcia J, Cruz C, et al. Efficacy, safety, and immunogenicity of a meningococcal group B(15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine 1995; 13:821-9.
11. de Moraes JC, Perkins BA, Camargo MCC, et al. Protective efficacy of a serogroup B meningococcal vaccine in São Paulo, Brazil. Lancet 1992;340:1074-8.
12. Broome CV. The carrier state: Neisseria meningitidis. J Antimicrob Chemother 1986;18:25-34.
13. Devine LF, Johnson DP, Hagerman CR, Pierce WE, Rhode SL, Peckinpaugh RO. Rifampin levels in serum and saliva and effect on the meningococcal carriage state. JAMA 1970; 214:1055-9.
14. Beaty HN. Rifampin and minocycline in meningococcal disease. Rev Infect Dis 1983;5(Suppl 3):S451-8.
15. Kuhns DM, Nelson CT, Feldman HA, Kuhn LR. The prophylactic value of sulfadiazine in the control of meningococcic meningitis. JAMA 1943;123:335-9.
16. Jacobson JA, Chester TJ, Fraser DW. An epidemic of disease due to serogroup B Neisseria meningitidis in Alabama: report of an investigation and community-wide prophylaxis with a sulfonamide. J Infect Dis 1977;136:104-7.
17. Nicolle LE, Postl B, Kotelewetz E, et al. Chemoprophylaxis for Neisseria meningitidis in an isolated Artic community. J Infect Dis 1982;145:103-9.
18. Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States: an emerging threat. JAMA 1995;273:383-94.
19. Selander RK, Caugant DA, Ochman H, Musser JM, Gilmour MN, Whittam TS. Methods of multilocus enzyme electrophoresis for bacterial population genetics and systematics. Appl Environ Microbiol 1986;51:873-84.
20. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibiity tests for bacteria that grow aerobically. Document M7-A2. Villanova, PA: National Committee for Clinical Laboratory Standards, 1990.
21. Jackson LA, Wenger JD, Meningococcal Disease Study Group. Laboratory-based surveillance for meningococcal disease in selected areas: United States, 1989-1991. MMWR 1993;42(SS-2):21-30.
22. Beam WE, Newberg NR, Devine LF, Pierce WE, Davies JA. The effect of rifampin on the nasopharyngeal carriage of Neisseria meningitidis in a military population. J Infect Dis 1971;124:39-46.
23. Weidmer CE, Dunkel TB, Pettyjohn FS, Smith CD, Leibovitz A. Effectiveness of rifampin in eradicating the meningococcal carrier state in a relatively closed population: emergence of resistant strains. J Infect Dis 1971;124:172-8.
24. Deal WB, Sanders E. Efficacy of rifampin in the treatment of meningococcal carriers. N Engl J Med 1969;281:641-5.
25. Beaty HN. Rifampin and minocycline in meningococcal disease. Rev Infect Dis 1983;5:S451-8.
26. Devine LF, Johnson DP, Hagerman CR, Pierce WE, Rhode SL, Peckinpaugh RO. Rifampin levels in serum and saliva and effect on the meningococcal carrier state. JAMA 1970; 214:1055-9.
27. Levy DI, del Rio C, Stephens DS. Meningococcemia in identical twins: changes in serum susceptibility after rifampin chemoprophylaxis. J Infect Dis 1988;157:1064-8.
28. Cooper ER, Ellison RT III, Smith GS, Blaser MJ, Reller LB, Paisley JW. Rifampin-resistant meningococcal disease in a contact patient given prophylatic rifampin. J Pediatr 1986; 108:93-6.
29. Hassan King MK, Wall RA, Greenwood BM. Meningococcal carriage, meningococcal disease and vaccination. J Infect Dis 1988;16:55-9.
30. Feigin RD, Baker CJ, Herwaldt LA, Lampe RM, Mason EO, Whitney SE. Epidemic meningococcal disease in an elementary-school classroom. N Engl J Med 1982;307:1255-7.
31. Morrow HW, Slaten DD, Reingold AL, Werner SB, Fenstersheib MD. Risk factors associated with a school-related outbreak of serogroup C meningococcal disease. Pediatr Infect Dis J 1990;9:394-8.
32. Harrison LH, Armstrong CW, Jenkins SR, et al. A cluster of meningococcal disease on a school bus following epidemic influenza. Arch Intern Med 1991;151:1005-9.
33. Lystad A, Aasen S. The epidemiology of meningococcal disease in Norway, 1975-91. NIPH Ann 1991;14:4927-31.
34. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus: IV. Immunogenicity of group A and group C meningococcus in human volunteers. J Exp Med 1969;129:1367-84.